B
Bull
Bull · 25%NMRA
$1.86
シナリオ価格
$1.390
-0.085 (-6.08%)終値時点
Loading chart…
- High
- 1.510
- Open
- 1.500
- VWAP
- 1.43
- Vol
- 696.28K
- Mkt Cap
- 1.47B
- Low
- 1.380
- Amount
- 993.37K
- EV/EBITDA, TTM
- 0.00
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
AI analysis of Neumora Therapeutics Inc (NMRA)
sellNeumora Therapeutics Inc is not a good buy right now due to significant financial losses and a declining stock price. The current price is $1.39, and the company has reported a net loss of $43.1 million for Q2 2026, which is a concern for long-term viability. Additionally, the RSI is at 30.313, indicating the stock is oversold but may not recover soon given the negative sentiment and recent downgrades from analysts.
バリュエーション指標
The current forward P/E ratio for Neumora Therapeutics Inc (NMRA) is 0.00, compared to its 5-year average forward P/E of -4.80.
Alphio AI Price Scenarios for NMRA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NMRA
イベントタイムライン
ニュース
9.508-14NASDAQ.COMNeumora Reports Q2 2026 Financials and Leadership Changes
8.507-27NewsfilterNeumora's NMRA-215 Shows Promising Pre-Clinical Results for Obesity Treatment
8.506-19NASDAQ.COMBiotech Sector Sees FDA Approvals and Layoffs
2.006-17PRnewswireNeumora Therapeutics Faces Stock Collapse After Failed Trials
- 9.506-16Newsfilter
Neumora Therapeutics Shares Plunge Nearly 50% After Trial Failures
NMRA FAQ — answered by Alphio AI
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Neumora Therapeutics Inc is not a good buy right now due to significant financial losses and a declining stock price. The current price is $1.39, and the company has reported a net loss of $43.1 million for Q2 2026, which is a concern for long-term viability. Additionally, the RSI is at 30.313, indicating the stock is oversold but may not recover soon given the negative sentiment and recent downgrades from analysts.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。